Tae Min Kim

Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer

Yun‐Gyoo Lee, Eunyoung Lee, Soo‐Mee Bang et al. · Thrombosis and Haemostasis · 2014 · 84 citations

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 70 citations · Full text

Met Amplification, Medicine, Pathology +8

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06)

Su Jin Lee, Tae Min Kim, Yu Jung Kim et al. · The Oncologist · 2015 · 68 citations · Full text

First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.

Sreenivasa R Chandana, Noura J. Choudhury, Afshin Dowlati et al. · Journal of Clinical Oncology · 2024 · 21 citations

Sez6 Expression, Immunology, First-in-human Study +21

SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL)

Ranjana H. Advani, Michael Dickinson, Christopher P. Fox et al. · Blood · 2024 · 14 citations · Full text